Trapping poly(ADP-Ribose) polymerase

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 3, 2015, Pages 446-457

  Shen, Yuqiao ^a   Aoyagi Scharber, Mika ^a   Wang, Bing ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 906894; A 927929; ADENOSINE; BIOLOGICAL MARKER; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FR 257517; HYDAMTIQ; IRINOTECAN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PHOSPHATE; RUCAPARIB; TALAZOPARIB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CYTOTOXICITY; DNA DAMAGE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME STRUCTURE; GENOTOXICITY; HUMAN; IC50; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84936802915     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.222448     Document Type: Review

References (118)

1. Ali AA, Timinszky G, Arribas-Bosacoma R, Kozlowski M, Hassa PO, Hassler M, Ladurner AG, Pearl LH, and Oliver AW (2012) The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat Struct Mol Biol 19:685-692.
2. Amé JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, Muller S, Höger T, Ménissier-de Murcia J, and de Murcia G (1999) PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 274:17860-17868.
3. Aoyagi-Scharber M, Gardberg AS, Yip BK, Wang B, Shen Y, and Fitzpatrick PA (2014) Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone. Acta Crystallogr F Struct Biol Commun 70:1143-1149.
4. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790.
5. Audebert M, Salles B, and Calsou P (2004) Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 279:55117-55126.
6. Bell CE and Eisenberg D (1996) Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry 35:1137-1149.
7. Benjamin RC and Gill DM (1980) Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks. J Biol Chem 255:10502-10508.
8. Beretta GL, Perego P, and Zunino F (2006) Mechanisms of cellular resistance to camptothecins. Curr Med Chem 13:3291-3305.
9. Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, and Dent P (2013) PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther 14:458-465.
10. Bouwman P and Jonkers J (2014) Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 20:540-547.
11. Bowman KJ, Newell DR, Calvert AH, and Curtin NJ (2001) Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84:106-112.
12. Bryant HE and Helleday T (2006) Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 34:1685-1691.
13. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, and Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917.
14. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, and Hemann MT (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 105:9053-9058.
15. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, et al. (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96:56-67.
16. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, et al. (2013) Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 19:6322-6328.
17. Cistulli C, Lavrik OI, Prasad R, Hou E, and Wilson SH (2004) AP endonuclease and poly(ADP-ribose) polymerase-1 interact with the same base excision repair intermediate. DNA Repair (Amst) 3:581-591.
18. Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12:801-817.
19. Curtin NJ and Szabo C (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 34:1217-1256.
20. Das BB, Huang SY, Murai J, Rehman I, Amé JC, Sengupta S, Das SK, Majumdar P, Zhang H, Biard D, et al. (2014) PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 42:4435-4449.
21. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, and Newell DR (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6: 2860-2867.
22. Durkacz BW, Omidiji O, Gray DA, and Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283:593-596.
23. Ekblad T, Camaioni E, Schüler H, and Macchiarulo A (2013) PARP inhibitors: polypharmacology versus selective inhibition. FEBS J 280:3563-3575.
24. Eng WK, Faucette L, Johnson RK, and Sternglanz R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760.
25. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921.
26. Feng Y, Shen Y, and Wang E (2014) Talazoparib (BMN-673) as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2014 Nov 18-21; Barcelona, Spain.
27. Ferraris DV (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 53:4561-4584.
28. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, et al. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512-2519.
29. Gandhi VB, Luo Y, Liu X, Shi Y, Klinghofer V, Johnson EF, Park C, Giranda VL, Penning TD, and Zhu GD (2010) Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem Lett 20:1023-1026.
30. Gangloff AR, Brown J, de Jong R, Dougan DR, Grimshaw CE, Hixon M, Jennings A, Kamran R, Kiryanov A, O'Connell S, et al. (2013) Discovery of novel benzo[b][1,4] oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. Bioorg Med Chem Lett 23:4501-4505.
31. Gilabert M, Launay S, Ginestier C, Bertucci F, Audebert S, Pophillat M, Toiron Y, Baudelet E, Finetti P, Noguchi T, et al. (2014) Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. PLoS One 9:e104302.
32. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, and Helleday T (2010) Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70:5389-5398.
33. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, et al. (2014) Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 5:5637-5650.
34. Haince JF, McDonald D, Rodrigue A, Déry U, Masson JY, Hendzel MJ, and Poirier GG (2008) PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem 283:1197-1208.
35. Hassler M and Ladurner AG (2012) Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases. Curr Opin Struct Biol 22:721-729.
36. Hattori K, Kido Y, Yamamoto H, Ishida J, Kamijo K, Murano K, Ohkubo M, Kinoshita T, Iwashita A, Mihara K, et al. (2004) Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose) polymerase. J Med Chem 47:4151-4154.
37. Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5:387-393.
38. Hopkins T, Solomon L, Shi YH, Rodriguez L, Donawho C, DiGiammorino E, Panchal S, Olson A, Stolarik D, Osterling D, et al. (2014) PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism (Abstract). Eur J Cancer 50:82-83.
39. Horton JK, Stefanick DF, Naron JM, Kedar PS, and Wilson SH (2005) Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure. J Biol Chem 280:15773-15785.
40. Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, and Wilson SH (2014) Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res 12:1128-1139.
41. Horton JK and Wilson SH (2013a) Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res 11:13-18.
42. Horton JK and Wilson SH (2013b) Strategic combination of DNA-damaging agent and PARP inhibitor results in enhanced cytotoxicity. Front Oncol 3:257.
43. Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, and Cushman M (2005) Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 48:4803-4814.
44. Iwashita A, Hattori K, Yamamoto H, Ishida J, Kido Y, Kamijo K, Murano K, Miyake H, Kinoshita T, Warizaya M, et al. (2005) Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett 579:1389-1393.
45. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, et al. (2011) Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 17:875-882.
46. Juarez-Salinas H, Sims JL, and Jacobson MK (1979) Poly(ADP-ribose) levels in carcinogen-treated cells. Nature 282:740-741.
47. Kedar PS, Stefanick DF, Horton JK, and Wilson SH (2012) Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res 10:360-368.
48. Kinoshita T, Nakanishi I, Warizaya M, Iwashita A, Kido Y, Hattori K, and Fujii T (2004) Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett 556:43-46.
49. Krishnakumar R and Kraus WL (2010) The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39:8-24.
50. Langelier MF and Pascal JM (2013) PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 23:134-143.
51. Langelier MF, Planck JL, Roy S, and Pascal JM (2011) Crystal structures of poly (ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J Biol Chem 286: 10690-10701.
52. Langelier MF, Planck JL, Roy S, and Pascal JM (2012) Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336: 728-732.
53. Langelier MF, Servent KM, Rogers EE, and Pascal JM (2008) A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J Biol Chem 283:4105-4114.
54. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, and Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767.
55. Lindahl T (1993) Instability and decay of the primary structure of DNA. Nature 362: 709-715.
56. Lindgren AE, Karlberg T, Thorsell AG, Hesse M, Spjut S, Ekblad T, Andersson CD, Pinto AF, Weigelt J, Hottiger MO, et al. (2013) PARP inhibitor with selectivity toward ADP-ribosytransferase ARTD3/PARP3. ACS Chem Biol 8:1698-1703.
57. Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, et al. (2009) Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 7:1686-1692.
58. Loeffler PA, Cuneo MJ, Mueller GA, DeRose EF, Gabel SA, and London RE (2011) Structural studies of the PARP-1 BRCT domain. BMC Struct Biol 11:37.
59. Lord CJ and Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287-294.
60. Luo X and Kraus WL (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26:417-432.
61. Lupo B and Trusolino L (2014) Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta 1846:201-215.
62. Mansoorabadi SO, Wu M, Tao Z, Gao P, Pingali SV, Guo L, and Liu HW (2014) Conformational activation of poly(ADP-ribose) polymerase-1 upon DNA binding revealed by small-angle X-ray scattering. Biochemistry 53:1779-1788.
63. Marchand JR, Carotti A, Passeri D, Filipponi P, Liscio P, Camaioni E, Pellicciari R, Gioiello A, and Macchiarulo A (2014) Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy. Biochim Biophys Acta 1844:1765-1772.
64. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115.
65. Miao ZH, Player A, Shankavaram U, Wang YH, Zimonjic DB, Lorenzi PL, Liao ZY, Liu H, Shimura T, Zhang HL, et al. (2007) Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 67: 8752-8761.
66. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et al. (2013) Cisplatin resistance associated with PARP hyperactivation. Cancer Res 73:2271-2280.
67. Miranda EA, Dantzer F, O'Farrell M, de Murcia G, and de Murcia JM (1995) Characterisation of a gain-of-function mutant of poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 212:317-325.
68. Miyashiro J, Woods KW, Park CH, Liu X, Shi Y, Johnson EF, Bouska JJ, Olson AM, Luo Y, Fry EH, et al. (2009) Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett 19: 4050-4054.
69. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, and Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588-5599.
70. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, and Pommier Y (2014a) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13:433-443.
71. Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, and Pommier Y (2014b) Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349:408-416.
72. Narwal M, Venkannagari H, and Lehtiö L (2012) Structural basis of selective inhibition of human tankyrases. J Med Chem 55:1360-1367.
73. Nitiss J and Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85:7501-7505.
74. Nowsheen S, Cooper T, Stanley JA, and Yang ES (2012) Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 7:e46614.
75. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, and Pritchard KI (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644-650.
76. Papeo G, Casale E, Montagnoli A, and Cirla A (2013) PARP inhibitors in cancer therapy: an update. Expert Opin Ther Pat 23:503-514.
77. Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, and Kaufmann SH (2012) Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287:4198-4210.
78. Patel MR, Bhatt A, Steffen JD, Chergui A, Murai J, Pommier Y, Pascal JM, Trombetta LD, Fronczek FR, and Talele TT (2014) Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors. J Med Chem 57: 5579-5601.
79. Pellicciari R, Camaioni E, Gilbert AM, Macchiarulo A, Bikker JA, Shah F, Bard J, Constantino G, Gioiello A, Robertson GM, et al. (2011) Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: from TIQ-A to HYDAMTIQ. Med Chem Commun 2:559-565.
80. Peng G and Lin SY (2011) Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J Clin Oncol 2:73-79.
81. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, et al. (2009) Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52:514-523.
82. Penning TD, Zhu GD, Gong J, Thomas S, Gandhi VB, Liu X, Shi Y, Klinghofer V, Johnson EF, Park CH, et al. (2010) Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. J Med Chem 53:3142-3153.
83. Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, et al. (2013) A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One 8:e61520.
84. Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, et al. (2012) Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. PLoS One 7:e50494.
85. Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, and Pommier Y (2009) Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther 8: 1878-1884.
86. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, et al. (2013) A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 71:1191-1199.
87. Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8:82-95.
88. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, et al. (2006) Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 81:179-229.
89. Pommier Y, Leo E, Zhang H, and Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421-433.
90. Pommier Y and Marchand C (2011) Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 11:25-36.
91. Pommier Y, Pourquier P, Urasaki Y, Wu J, and Laco GS (1999) Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 2:307-318.
92. Rasheed ZA and Rubin EH (2003) Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22:7296-7304.
93. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, and Hol WG (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279:1504-1513.
94. Rehman F, Elliott R, Brough R, Frankum J, Ragab A, Lord CJ, and Ashworth A (2012) Developing rational drug combination strategies for PARP inhibitors. J Clin Oncol 30 (suppl; abstr 3050).
95. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, and Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301.
96. Ruf A, Rolli V, de Murcia G, and Schulz GE (1998) The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J Mol Biol 278:57-65.
97. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, and Wick W (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14:2900-2908.
98. Satoh MS and Lindahl T (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356:356-358.
99. Schreiber V, Dantzer F, Ame JC, and de Murcia G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528.
100. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, and Ashworth A (2013) BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19:5003-5015.
101. Singh A, Bartosz C, Jia W, Clark K, Dering J, Anderson L, Federman N, Eilber FC, Shen Y, Finn R, et al. (2013) Mechanisms of resistance to the PARP inhibitor BMN 673 in Ewing's sarcoma. Connective Tissue Oncology Society 18th Annual Meeting; 2013 30 Oct-2 Nov; New York, NY.
102. Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, et al. (2015) Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21:819-832.
103. Solomon L, Hopkins T, Shi Y, Ellis P, Donawho C, Johnson EF, Fang G, and Maag D (2014) Veliparib (ABT-888) potentiates the cytotoxic activity of DNA alkylating agents by trapping PARP onto damaged chromatin. Annual Meeting of the American Association for Cancer Research; 2014 5-9 Apr; San Diego, CA.
104. Steffen JD, Brody JR, Armen RS, and Pascal JM (2013) Structural implications for selective targeting of PARPs. Front Oncol 3:301.
105. Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, et al. (2014) Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res 74:31-37.
106. Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB, 3rd, Bahrami A, et al. (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 9:829-841.
107. Ström CE, Johansson F, Uhlén M, Szigyarto CA, Erixon K, and Helleday T (2011) Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 39:3166-3175.
108. Tang Y, Dai Y, Grant S, and Dent P (2012) Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol Ther 13:379-388.
109. Turner NC and Ashworth A (2011) Biomarkers of PARP inhibitor sensitivity. Breast Cancer Res Treat 127:283-286.
110. von Euw EM, Gong KW, Rong HM, O'Brien N, Signh A, Shen Y, Post L, Finn RS, Chmielowski B, and Slamon DJ (2014) Combination of a novel PARP inhibitor, BMC 673, with temozolomide for the treatment of melanoma (Abstract). Pigment Cell Melanoma Res 26:1011.
111. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, Pol E, Frostell Å, Ekblad T, Öncü D, et al. (2012) Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 30:283-288.
112. Wendorff TJ, Schmidt BH, Heslop P, Austin CA, and Berger JM (2012) The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol 424:109-124.
113. Węsierska-Gądek J and Heinzl S (2014) Interactions between ataxia telangiectasia mutated kinase inhibition, poly(ADP-ribose) polymerase-1 inhibition and BRCA1 status in breast cancer cells. J Cancer Prev 19:125-136.
114. Wiholm BE and Myrhed M (1993) Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 44:589-591.
115. Ye N, Chen CH, Chen T, Song Z, He JX, Huan XJ, Song SS, Liu Q, Chen Y, Ding J, et al. (2013) Design, synthesis, and biological evaluation of a series of benzo[de] [1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors. J Med Chem 56:2885-2903.
116. Yelamos J, Farres J, Llacuna L, Ampurdanes C, and Martin-Caballero J (2011) PARP-1 and PARP-2: new players in tumour development. Am J Cancer Res 1: 328-346.
117. Zhang J, Stevens MF, and Bradshaw TD (2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5:102-114.
118. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, and Pommier Y (2011) Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 39:3607-3620.